KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Accumulated Expenses (2018 - 2025)

Castle Biosciences' Accumulated Expenses history spans 7 years, with the latest figure at $38.3 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 17.61% year-over-year to $38.3 million; the TTM value through Dec 2025 reached $38.3 million, up 17.61%, while the annual FY2025 figure was $38.3 million, 17.61% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $38.3 million at Castle Biosciences, up from $31.8 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $38.3 million in Q4 2025 and bottomed at $5.2 million in Q1 2021.
  • The 5-year median for Accumulated Expenses is $18.7 million (2022), against an average of $20.0 million.
  • The largest annual shift saw Accumulated Expenses soared 90.75% in 2021 before it grew 12.47% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $15.5 million in 2021, then skyrocketed by 57.32% to $24.4 million in 2022, then increased by 18.83% to $28.9 million in 2023, then increased by 12.47% to $32.6 million in 2024, then increased by 17.61% to $38.3 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Accumulated Expenses are $38.3 million (Q4 2025), $31.8 million (Q3 2025), and $25.0 million (Q2 2025).